Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for Ischemia-Reperfusion Injury in TKR
NCT02648958Completed
- Sponsor
- Yonsei University
- Start
- Jan 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine in ischemia-reperfusion injury (IRI) (2 arms), sponsored by Yonsei University. Primary endpoint: changes of malondialdehyde at 1 day. Started Jan 2016; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT02648958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02648958.